Okla. Stat. tit. 63, § 63-1-757.7

The State Board of Medical Licensure and Supervision and the

State Board of Osteopathic Examiners shall adopt a certification

system for any physician intending to provide abortion-inducing

drugs to patients in the state. Individuals or physicians providing

abortion-inducing drugs in other states are not automatically

certified in this state, and shall be fully certified under this law

prior to providing any abortion-inducing drugs to any pregnant women

in this state. To be eligible to be certified under this section

physicians shall:

1. Be fully licensed by and in good standing with either the

State Board of Medical Licensure and Supervision or the State Board

of Osteopathic Examiners to practice medicine in the state;

2. Examine any patient in person prior to providing abortion-

inducing drugs;

3. Sign an annual "Dispensing Agreement Form", to be developed

and provided by the physician's state licensing board, before

providing abortion-inducing drugs;

4. Inform the patient of gestational age-specific risks of

using abortion-inducing drugs;

5. Assess for signs of domestic abuse, reproductive control,

human trafficking and other signals of coerced abortion, per current

state guidelines;

6. Adequately inform the patient of gestational age-specific

age risks of using abortion-inducing drugs;

7. Inform the patient that she may see the remains of her

unborn child in the process of completing the abortion;

Oklahoma Statutes - Title 63. Public Health and Safety Page 458

8. Inform the patient that studies show that babies born

following the abortion reversal process have a rate of birth defects

no higher than the general population;

9. Inform the patient that studies show that following this

reversal process or otherwise treating a woman with progesterone

during pregnancy does not lead to increased mortality rates;

10. Refrain from knowingly supplying abortion-inducing drugs to

patients who present with any of the following:

a. absence of a pregnancy,

b. being post-seventy days gestation or post-ten weeks of

pregnancy, and

c. having risk factors associated with abortion-inducing

drugs including, but not limited to:

(1) ectopic pregnancies,

(2) problems with the adrenal glands near the

kidneys,

(3) being treated with long-term corticosteroid

therapy,

(4) allergic reactions to abortion-inducing drugs,

mifepristone, misoprostol or similar drugs,

(5) bleeding problems or is taking anticoagulant drug

products,

(6) has inherited porphyria,

(7) has an intrauterine device in place, or

(8) being Rh Negative, requiring administration of

Rhogam before providing abortion-inducing drugs;

11. Provide or refer for emergency surgical intervention in

cases of incomplete abortion, severe bleeding or other medical

complications, through maintaining hospital admitting privileges or

entering into a written agreement with an associated physician as

specified in Section 8 of this act;

12. Assure patient access to medical facilities equipped to

provide blood transfusions and resuscitation or other necessary

treatments, if necessary;

13. Sign, and ensure that the patient signs, all legally

required informed consent material, providing patient with a copy

showing both signatures, and placing the original in the patient's

medical record;

14. Record the serial number from each package of each

abortion-inducing drug given to the patient in her medical record;

15. Submit a written protocol of how efforts will be made to

schedule with the patient the medically indicated follow-up

appointment within fourteen (14) days to assure a completed

abortion;

16. Report to the State Board of Pharmacy, the physician's

state licensing board and the Food and Drug Administration, any

Oklahoma Statutes - Title 63. Public Health and Safety Page 459

death associated with abortion-inducing drugs with the following

guidelines:

a. the patient shall be noted by a non-identifiable
low-up

appointment within fourteen (14) days to assure a completed

abortion;

16. Report to the State Board of Pharmacy, the physician's

state licensing board and the Food and Drug Administration, any

Oklahoma Statutes - Title 63. Public Health and Safety Page 459

death associated with abortion-inducing drugs with the following

guidelines:

a. the patient shall be noted by a non-identifiable

reference and the serial number from each package of

abortion-inducing drug given, whether or not

considered drug-related,

b. this shall be done as soon as possible but no later

than fifteen (15) calendar days from the initial

receipt of the information by the physician, and

c. this requirement does not affect the physician's other

reporting and follow-up requirements under the

Oklahoma Abortion-Inducing Drug Certification Program

or any additional requirements by another department

that oversees the abortion industry in this state;

17. Submit a written protocol of how complications will be

handled by the certified physician and submit a copy of a signed

contract with an associated physician credentialed to handle certain

complications as outlined in Section 8 of this act;

18. Abide by all applicable state and federal laws regarding

medical records retention, confidentiality and privacy; and

19. Agree to follow and document compliance with all other

legally required conditions for performing abortion in the state

where the patient presents for her appointment including, but not

limited to, waiting periods, informed consent requirements,

statistical reporting, parental consent or notification and required

inspections.